IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)
In this month’s “Hot Topic,” Dr. Curt Hanson will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53 sequencing in these patients.
Видео IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL) канала Mayo Clinic Laboratories
Видео IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL) канала Mayo Clinic Laboratories
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Chronic Lymphocytic Leukemia (CLL)
Venetoclax + Obinutuzumab: Impact on CLL Management
Is It Time to Treat Your CLL? What You Need to Know
Combination of Novel Agents in CLL: Is this the Final Answer?
MRD in AML: What is it and what do I do about it?
p53
Jennifer Woyach: Ibrutinib Outperforms Chemoimmunotherapy in CLL
What is chronic myelogenous leukemia? | Hematologic System Diseases | NCLEX-RN | Khan Academy
CLL Biology
CLL treatment New Options, More Hope
Pleural Mesothelioma
Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic
The BCR signaling pathway in CLL
p53 Structure and Function - Cell Cycle Regualtion & Apoptosis
Mantle Cell Lymphoma | Aggressive B-Cell Non-Hodgkin’s Lymphoma
Pathology-Acute Myeloid Leukemia | AML made easy | Clinical features and Diagnosis #acuteleukemias
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Leukemia Patient Story: My 1st Symptoms for CLL | Stephen's Story (1/5)
The Genome of Diffuse Large B-cell Lymphoma